Global Search | Novartis

Hide Filters

Showing 712 results

Press release / Jun 02, 2018

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® Findings further support durability and…
Press release / Jul 30, 2018

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
Press release / Oct 27, 2018

Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in…
Ad hoc release / Oct 08, 2019

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
Press release / Jun 10, 2016

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder

EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
Press release / May 26, 2017

Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy[1] The overall intracranial response rate…
Press release / Apr 07, 2016

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP

EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
Press release / Sep 01, 2019

Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint

Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
Press release / Oct 24, 2017

Novartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisions

Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses…
Ad hoc release / Oct 18, 2018

Novartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance future

Hausse du chiffre d'affaires net de 6% (tcc[1], +3% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 750 millions (+37% tcc) grâce à une forte croissance en volume dans toutes…

‹ Previous page
1
…
52
53
54
55
56
57
58
…
72
› Next page